VGXI Inc., a contract developer and manufacturer (CDMO) specializing in nucleic acid biopharmaceuticals, has been accepted into the Biopharmaceutical Manufacturing Preparedness (BioMap) Consortium, an organization focused on expanding the United States’ biopharmaceutical industrial capabilities and bio-manufacturing output.
 
The BioMap Consortium is supported by the Pharmaceutical Countermeasure Infrastructure (PCI) Division and BioMap Branch of the Biomedical Advanced Research and Development Authority (BARDA).
 
With this acceptance, VGXI joins the ranks of more than 200+ member firms with the expressed mission of ensuring adequate manufacturing capabilities and developing biopharmaceutical products and related materials so that countermeasures and therapies can be rapidly delivered to civilian populations. With more than two decades of experience in plasmid DNA manufacturing, VGXI has the largest plasmid manufacturing capacity (4000L) in the world and provides the agility and scalability to support the development of next-generation therapeutics across all scales and stages – from preclinical research to full-scale commercial production.
 
Young Park, CEO at VGXI, celebrated the milestone by stating, “We are proud to be a part of the BioMap Consortium. Our demonstrated history of manufacturing solutions for public health allows VGXI to be a valuable contributor to this consortium and to support our fellow members and US-based biomanufacturing to address health-related threats to the nation’s public health.”

More VGXI News